Lonza Group, a Swiss supplier to the life science industries, has appointed Jeanne Thoma as chief operating officer of Lonza’s Microbial Control sector (LMC), which will be created following the acquisition of Arch Chemicals.
Thoma will assume the role upon the successful closing of the acquisition and at this time will also become a member of the Lonza management committee reporting to chief executive Stefan Borgas.
Last month Lonza announced its intention to acquire Arch Chemicals. The acquisition is currently subject to the approval of the regulatory authorities and is expected to close later this year.
Thoma will shape the organisational structure of the Microbial Control sector that will be created, appoint its leadership team and drive the preparations for the integration of both organisations. She will be based in Basel.
Thoma joined Lonza in 2004 and since 2007 has been global head of the Microbial Control business unit and president of Lonza Inc.
Prior to joining Lonza, she spent 15 years at BASF holding various executive positions in sales, marketing, logistics and supply chain.
Lonza appoints Jeanne Thoma
As future chief operating officer of the Microbial Control sector
You may also like
Ingredients
Staying ahead of the ADC curve
Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules
